文献速递认知障碍与痴呆

布瑞哌唑治疗阿尔茨海默病痴呆激越:一项随机临床试验

Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2023-01-01

这项12周、双盲、安慰剂对照、固定剂量、平行组随机临床试验在欧洲和美国123个中心进行,纳入345例阿尔茨海默病痴呆伴激越患者,按2:1随机接受布瑞哌唑(228例,其中2 mg/d或3 mg/d)或安慰剂(117例)。布瑞哌唑2或3 mg组在12周时Cohen-Mansfield激越量表总分较基线的改善显著优于安慰剂组(最小二乘均数差-5.32,95%CI -8.77至-1.87,P=0.003)。布瑞哌唑总体耐受性良好。

要点

  • 布瑞哌唑2或3 mg组12周CMAI总分较基线变化-22.6,安慰剂组-17.3,组间差异显著。
  • 未出现布瑞哌唑组发生率≥5%且高于安慰剂组的不良事件。
  • 因不良事件停药比例布瑞哌唑组5.3%(12/226),安慰剂组4.3%(5/116)。

核心结论

  • 在阿尔茨海默病痴呆伴激越患者中,布瑞哌唑2或3 mg治疗12周在改善激越方面较安慰剂显示出统计学显著改善。
  • 布瑞哌唑在这类脆弱患者人群中12周内总体耐受性良好。

研究设计与样本

  • 随机临床试验,12周、双盲、安慰剂对照、固定剂量、平行组设计。
  • 2018年5月至2022年6月在欧洲和美国123个临床试验中心进行。
  • 共345例患者随机接受布瑞哌唑(n=228)或安慰剂(n=117),比例2:1;布瑞哌唑组内再按1:2随机接受2 mg/d或3 mg/d固定剂量。
  • 纳入在护理机构或社区环境中伴激越的阿尔茨海默病痴呆患者,允许稳定使用阿尔茨海默病药物。

主要发现

  • 布瑞哌唑2或3 mg组(n=225)CMAI总分从基线至第12周的最小二乘均数差为-5.32(95%CI -8.77至-1.87,P=0.003,Cohen d效应量0.35),优于安慰剂组(n=116)。
  • 布瑞哌唑组基线CMAI总分80.6,平均变化-22.6;安慰剂组基线79.2,平均变化-17.3。
  • 未出现布瑞哌唑组发生率≥5%且高于安慰剂组的不良事件。
  • 因不良事件停药比例:布瑞哌唑组12/226(5.3%),安慰剂组5/116(4.3%)。
  • 完成率:布瑞哌唑组198/228(86.8%),安慰剂组104/117(88.9%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Agitation is a prevalent, distressing, and burdensome manifestation of Alzheimer dementia in need of an efficacious, safe, and well-tolerated treatment. OBJECTIVE: To confirm the efficacy, safety, and tolerability of brexpiprazole in patients with agitation in Alzheimer dementia. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was a 12-week, double-blind, placebo-controlled, fixed-dose, parallel-arm trial that ran from May 2018 to June 2022 at 123 clinical trial sites in Europe and the United States. Participants included patients with agitation in Alzheimer dementia in a care facility or community-based setting. Stable Alzheimer disease medications were permitted. INTERVENTIONS: In this 2-arm trial, patients were randomized to receive oral brexpiprazole or placebo (2:1 ratio) for 12 weeks. Within the brexpiprazole arm, patients were further randomized to receive fixed doses of 2 mg/d or 3 mg/d in a 1:2 ratio. MAIN OUTCOMES AND MEASURES: The primary end point was change in Cohen-Mansfield Agitation Inventory total score (which measures the frequency of 29 agitated behaviors) from baseline to week 12 for brexpiprazole, 2 or 3 mg, vs placebo. Safety was assessed by standard measures, including treatment-emergent adverse events. RESULTS: A total of 345 patients were randomized to receive brexpiprazole (n = 228) or placebo (n = 117); completion rates were 198 (86.8%) for brexpiprazole and 104 (88.9%) for placebo. Mean (SD) age was 74.0 (7.5) years, and 195 of 345 patients were female (56.5%). Patients receiving brexpiprazole, 2 or 3 mg (n = 225), demonstrated statistically significantly greater improvement than those taking placebo (n = 116) in Cohen-Mansfield Agitation Inventory total score from baseline to week 12 (brexpiprazole baseline, 80.6, mean change, -22.6; placebo baseline, 79.2, mean change, -17.3; least-squares mean difference, -5.32; 95% CI, -8.77 to -1.87; P = .003; Cohen d effect size, 0.35). No treatment-emergent adverse events had an incidence of 5% or more with brexpiprazole and greater incidence than placebo. The proportion of patients who discontinued because of adverse events was 12 of 226 (5.3%) for brexpiprazole and 5 of 116 (4.3%) for placebo. CONCLUSIONS AND RELEVANCE: In this study, patients with Alzheimer dementia who took brexpiprazole, 2 or 3 mg, showed a statistically significant improvement vs placebo in agitation over 12 weeks. Brexpiprazole was generally well tolerated over 12 weeks in this vulnerable patient population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03548584.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Lee D, Slomkowski M, Hefting N, et al. Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 37930669. doi:10.1001/jamaneurol.2023.3810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。